PMID- 37261291
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230604
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 14
DP  - 2023
TI  - Perspectives on precision cut lung slices-powerful tools for investigation of 
      mechanisms and therapeutic targets in lung diseases.
PG  - 1162889
LID - 10.3389/fphar.2023.1162889 [doi]
LID - 1162889
AB  - Precision cut lung slices (PCLS) have emerged as powerful experimental tools for 
      respiratory research. Pioneering studies using mouse PCLS to visualize 
      intrapulmonary airway contractility have been extended to pulmonary arteries and 
      for assessment of novel bronchodilators and vasodilators as therapeutics. 
      Additional disease-relevant outcomes, including inflammatory, fibrotic, and 
      regenerative responses, are now routinely measured in PCLS from multiple species, 
      including humans. This review provides an overview of established and innovative 
      uses of PCLS as an intermediary between cellular and organ-based studies and 
      focuses on opportunities to increase their application to investigate mechanisms 
      and therapeutic targets to oppose excessive airway contraction and fibrosis in 
      lung diseases.
CI  - Copyright (c) 2023 Lam, Lamanna, Organ, Donovan and Bourke.
FAU - Lam, Maggie
AU  - Lam M
AD  - Department of Pharmacology, Biomedicine Discovery Institute, Monash University, 
      Clayton, VIC, Australia.
AD  - Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical 
      Research, Clayton, VIC, Australia.
AD  - Department of Molecular and Translational Sciences, Monash University, Clayton, 
      VIC, Australia.
FAU - Lamanna, Emma
AU  - Lamanna E
AD  - Department of Pharmacology, Biomedicine Discovery Institute, Monash University, 
      Clayton, VIC, Australia.
AD  - Institut Pasteur, Unit of Antibodies in Therapy and Pathology, INSERM UMR1222, 
      Paris, France.
FAU - Organ, Louise
AU  - Organ L
AD  - Department of Pharmacology, Biomedicine Discovery Institute, Monash University, 
      Clayton, VIC, Australia.
FAU - Donovan, Chantal
AU  - Donovan C
AD  - School of Life Sciences, Faculty of Science, University of Technology Sydney, 
      Sydney, NSW, Australia.
AD  - Hunter Medical Research Institute and The University of Newcastle, Newcastle, 
      NSW, Australia.
FAU - Bourke, Jane E
AU  - Bourke JE
AD  - Department of Pharmacology, Biomedicine Discovery Institute, Monash University, 
      Clayton, VIC, Australia.
AD  - Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical 
      Research, Clayton, VIC, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230516
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC10228656
OTO - NOTNLM
OT  - PCLS
OT  - airway
OT  - bronchodilator
OT  - fibrosis
OT  - intrapulmonary artery
OT  - standardisation
OT  - vasodilator
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/06/01 13:10
MHDA- 2023/06/01 13:11
PMCR- 2023/05/16
CRDT- 2023/06/01 10:39
PHST- 2023/02/10 00:00 [received]
PHST- 2023/04/19 00:00 [accepted]
PHST- 2023/06/01 13:11 [medline]
PHST- 2023/06/01 13:10 [pubmed]
PHST- 2023/06/01 10:39 [entrez]
PHST- 2023/05/16 00:00 [pmc-release]
AID - 1162889 [pii]
AID - 10.3389/fphar.2023.1162889 [doi]
PST - epublish
SO  - Front Pharmacol. 2023 May 16;14:1162889. doi: 10.3389/fphar.2023.1162889. 
      eCollection 2023.